WALTHAM, Mass.--(BUSINESS WIRE)--Avedro, Inc. announced today that it has named Satish Herekar as its new Science Fellow. Herekar is a world-renowned researcher and entrepreneur in the fields of trans-epithelial drug delivery and accelerated cross-linking, and is co-Founder of Seros Medical. In his new role, he will be responsible for continuing Avedro’s momentum in cutting-edge trans-epithelial cross-linking research and innovation.
“I am honored to join the outstanding research team at Avedro”
Prior to joining Avedro, Herekar was co-Founder of Seros Medical/ PriaVision, where he initiated research and development in trans-epithelial riboflavin delivery techniques for rapid cross-linking, improved UVA crosslinking delivery devices, and other advanced uses of cross-linking for refractive correction. Herekar previously held roles of increasing seniority at Sunrise Technologies, Sepragen, Acuson, Cooper Vision, and General Electric. He is also the Founder of Bridge Labs, LLC.
“Satish is a talented addition to the Avedro Science team,” said David Muller, PhD, CEO of Avedro. “As leaders and innovators in the field of accelerated cross-linking, we are pleased to have one of the world’s most prolific researchers join our team to help continue the profound research momentum we have already achieved, and bring it to the next level.”
“I am honored to join the outstanding research team at Avedro,” commented Herekar. “I look forward to taking a significant role in a team of scientists which is at the cutting edge of research in this field.”
Herekar will be working with Avedro’s proprietary family of riboflavin formulations and the KXL® System for Accelerated Cross-linking. In this role, he will be reporting directly to the Chief Scientific Officer.
About Avedro, Inc.
Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking. The Company’s advanced cross-linking technology makes the treatment of keratoconus and post-LASIK ectasia faster, while also making possible an entirely new cross-linking procedure, Lasik Xtra®, intra-operative cross-linking following the creation of the LASIK flap and/or excimer laser ablation during LASIK or PRK. More than 50,000 eyes around the world have been treated with Avedro’s KXL ® System for Accelerated Cross-linking. Outside the US, Avedro has obtained CE Mark for its KXL System and its family of riboflavin products. Avedro’s products are not for sale in the US.